Literature DB >> 16440061

Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions.

Sang Sun Yoon1, Ray Coakley, Gee W Lau, Sergei V Lymar, Benjamin Gaston, Ahmet C Karabulut, Robert F Hennigan, Sung-Hei Hwang, Garry Buettner, Michael J Schurr, Joel E Mortensen, Jane L Burns, David Speert, Richard C Boucher, Daniel J Hassett.   

Abstract

Mucoid, mucA mutant Pseudomonas aeruginosa cause chronic lung infections in cystic fibrosis (CF) patients and are refractory to phagocytosis and antibiotics. Here we show that mucoid bacteria perish during anaerobic exposure to 15 mM nitrite (NO2) at pH 6.5, which mimics CF airway mucus. Killing required a pH lower than 7, implicating formation of nitrous acid (HNO2) and NO, that adds NO equivalents to cellular molecules. Eighty-seven percent of CF isolates possessed mucA mutations and were killed by HNO2 (3-log reduction in 4 days). Furthermore, antibiotic-resistant strains determined were also equally sensitive to HNO2. More importantly, HNO2 killed mucoid bacteria (a) in anaerobic biofilms; (b) in vitro in ultrasupernatants of airway secretions derived from explanted CF patient lungs; and (c) in mouse lungs in vivo in a pH-dependent fashion, with no organisms remaining after daily exposure to HNO2 for 16 days. HNO2 at these levels of acidity and NO2 also had no adverse effects on cultured human airway epithelia in vitro. In summary, selective killing by HNO2 may provide novel insights into the important clinical goal of eradicating mucoid P. aeruginosa from the CF airways.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16440061      PMCID: PMC1350997          DOI: 10.1172/JCI24684

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  53 in total

1.  Toxicity of peroxynitrite and related reactive nitrogen species toward Escherichia coli.

Authors:  J K Hurst; S V Lymar
Journal:  Chem Res Toxicol       Date:  1997-07       Impact factor: 3.739

2.  Anaerobic production of alginate by Pseudomonas aeruginosa: alginate restricts diffusion of oxygen.

Authors:  D J Hassett
Journal:  J Bacteriol       Date:  1996-12       Impact factor: 3.490

3.  Mucoid Pseudomonas aeruginosa and cystic fibrosis: resistance of the mucoid from to carbenicillin, flucloxacillin and tobramycin and the isolation of mucoid variants in vitro.

Authors:  J R Govan; J A Fyfe
Journal:  J Antimicrob Chemother       Date:  1978-05       Impact factor: 5.790

4.  Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis.

Authors:  Sang Sun Yoon; Robert F Hennigan; George M Hilliard; Urs A Ochsner; Kislay Parvatiyar; Moneesha C Kamani; Holly L Allen; Teresa R DeKievit; Paul R Gardner; Ute Schwab; John J Rowe; Barbara H Iglewski; Timothy R McDermott; Ronald P Mason; Daniel J Wozniak; Robert E W Hancock; Matthew R Parsek; Terry L Noah; Richard C Boucher; Daniel J Hassett
Journal:  Dev Cell       Date:  2002-10       Impact factor: 12.270

5.  Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients.

Authors:  Dieter Worlitzsch; Robert Tarran; Martina Ulrich; Ute Schwab; Aynur Cekici; Keith C Meyer; Peter Birrer; Gabriel Bellon; Jürgen Berger; Tilo Weiss; Konrad Botzenhart; James R Yankaskas; Scott Randell; Richard C Boucher; Gerd Döring
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

Review 6.  Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets.

Authors:  Daniel J Hassett; John Cuppoletti; Bruce Trapnell; Sergei V Lymar; John J Rowe; Sang Sun Yoon; George M Hilliard; Kislay Parvatiyar; Moneesha C Kamani; Daniel J Wozniak; Sung Hei Hwang; Timothy R McDermott; Urs A Ochsner
Journal:  Adv Drug Deliv Rev       Date:  2002-12-05       Impact factor: 15.470

Review 7.  An overview of the pathogenesis of cystic fibrosis lung disease.

Authors:  R C Boucher
Journal:  Adv Drug Deliv Rev       Date:  2002-12-05       Impact factor: 15.470

8.  Mucoid Pseudomonas aeruginosa in cystic fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection.

Authors:  J C Boucher; H Yu; M H Mudd; V Deretic
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

9.  A mechanism by which nitric oxide accelerates the rate of oxidative DNA damage in Escherichia coli.

Authors:  Anh N Woodmansee; James A Imlay
Journal:  Mol Microbiol       Date:  2003-07       Impact factor: 3.501

10.  Nitronyl nitroxides as probes to study the mechanism of vasodilatory action of nitrovasodilators, nitrone spin traps, and nitroxides: role of nitric oxide.

Authors:  E A Konorev; M M Tarpey; J Joseph; J E Baker; B Kalyanaraman
Journal:  Free Radic Biol Med       Date:  1995-02       Impact factor: 7.376

View more
  83 in total

1.  A biophysical model for integration of electrical, osmotic, and pH regulation in the human bronchial epithelium.

Authors:  Cibele V Falkenberg; Eric Jakobsson
Journal:  Biophys J       Date:  2010-04-21       Impact factor: 4.033

2.  Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: a phase I clinical study.

Authors:  Caroline Deppisch; Gloria Herrmann; Ute Graepler-Mainka; Hubertus Wirtz; Susanne Heyder; Corinna Engel; Matthias Marschal; Christopher C Miller; Joachim Riethmüller
Journal:  Infection       Date:  2016-02-09       Impact factor: 3.553

3.  Acidosis potentiates the host proinflammatory interleukin-1β response to Pseudomonas aeruginosa infection.

Authors:  Iviana M Torres; Yash R Patankar; Tamer B Shabaneh; Emily Dolben; Deborah A Hogan; David A Leib; Brent L Berwin
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

4.  When the party is over: a signal for dispersal of Pseudomonas aeruginosa biofilms.

Authors:  Tony Romeo
Journal:  J Bacteriol       Date:  2006-11       Impact factor: 3.490

Review 5.  Update in cystic fibrosis 2006.

Authors:  Frank J Accurso
Journal:  Am J Respir Crit Care Med       Date:  2007-04-15       Impact factor: 21.405

Review 6.  Chronic obstructive pulmonary disease (COPD): evaluation from clinical, immunological and bacterial pathogenesis perspectives.

Authors:  Daniel J Hassett; Michael T Borchers; Ralph J Panos
Journal:  J Microbiol       Date:  2014-03-01       Impact factor: 3.422

7.  Nutritional cues control Pseudomonas aeruginosa multicellular behavior in cystic fibrosis sputum.

Authors:  Kelli L Palmer; Lindsay M Aye; Marvin Whiteley
Journal:  J Bacteriol       Date:  2007-09-14       Impact factor: 3.490

8.  Myeloperoxidase-dependent oxidative metabolism of nitric oxide in the cystic fibrosis airway.

Authors:  Anna L P Chapman; Brian M Morrissey; Vihas T Vasu; Maya M Juarez; Jessica S Houghton; Chin-Shang Li; Carroll E Cross; Jason P Eiserich
Journal:  J Cyst Fibros       Date:  2010-01-15       Impact factor: 5.482

9.  Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes.

Authors:  Nicole Mayer-Hamblett; Margaret Rosenfeld; Ronald L Gibson; Bonnie W Ramsey; Hemantha D Kulasekara; George Z Retsch-Bogart; Wayne Morgan; Daniel J Wolter; Christopher E Pope; Laura S Houston; Bridget R Kulasekara; Umer Khan; Jane L Burns; Samuel I Miller; Lucas R Hoffman
Journal:  Am J Respir Crit Care Med       Date:  2014-08-01       Impact factor: 21.405

10.  Proteomic, microarray, and signature-tagged mutagenesis analyses of anaerobic Pseudomonas aeruginosa at pH 6.5, likely representing chronic, late-stage cystic fibrosis airway conditions.

Authors:  Mark D Platt; Michael J Schurr; Karin Sauer; Gustavo Vazquez; Irena Kukavica-Ibrulj; Eric Potvin; Roger C Levesque; Amber Fedynak; Fiona S L Brinkman; Jill Schurr; Sung-Hei Hwang; Gee W Lau; Patrick A Limbach; John J Rowe; Michael A Lieberman; Nicolas Barraud; Jeremy Webb; Staffan Kjelleberg; Donald F Hunt; Daniel J Hassett
Journal:  J Bacteriol       Date:  2008-01-18       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.